A5 Labs Appoints Senior Managers

MONTREAL, QUEBEC--(Marketwire - August 16, 2010) - A5 Laboratories Inc. (A5 Labs) (OTCBB: AFLB) today announced the appointment of Ms. Valentyna Navala to the position of Director of Microbiology and Interferon Clinical Programs and Mr. Chakib Rhofir to the position of Director of CRO Scientific Affairs.

Ms. Navala holds a B.Sc. in Microbiology as well as Certification from the Advanced Medical Studies Institute in Kiev. She spent over 20 years at the department of Clinical Diagnostics, Kiev Clinical Hospital and brings over 25 years experience in conducting laboratory trials as well as biochemical and clinical studies in the field of microbiology and virology. Ms. Navala will be responsible for all aspects of design and implementation of planned interferon related laboratory production and clinical programs.

Mr. Rhofir holds a B.Sc. and M.Sc. in Chemistry from University of Quebec in Montreal. He has over 18 years experience in analytical research and development as well as quality control and quality assurance. Mr. Rhofir’s has previously held research and development roles at national Institute of Scientific Research in Quebec as well as at National Research Council of Canada in Montreal. Mr. Rhofir will be responsible for design, conduct and completion of analytical research and development for both pharmaceutical and environmental testing clients.

About A5 Labs:

A5 Labs is a contract research based organization servicing the pharmaceutical and biotechnology companies in North America. The company utilizes its research capabilities to license and acquire novel biotechnology products for development and commercialization.

Safe Harbor Statement:

Except for historical information contained herein, the matters set forth above may be forward-looking statements that involve certain risks and uncertainties that could cause actual results to differ from those in the forward-looking statements. Words such as “anticipate”, “believe”, “estimate”, “expect”, “intend” and similar expressions, as they relate to A5 or its management, identify forward-looking statements. Such forward-looking statements are based on the current beliefs of management, as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors such as the competitive environment within the industry, the ability of A5 to continue to expand its operations, the level of costs incurred in connection with A5’s development efforts, economic conditions in the industry and A5’s financial strength. A5 does not undertake any obligation to update such forward-looking statements. Investors are also directed to consider all other risks and uncertainties.